natgillin/translations-raw huggingface dataset:
making a second modification of the mouse to add a nucleic acid sequence that confers upon the mouse ADAM6 activity that is functional in a male mouse, which nucleic acid sequence encodes a mouse ADAM6a protein or an ortholog, a homolog, or a functional fragment thereof, and a mouse ADAM6b protein or an ortholog, a homolog, or a functional fragment thereof, wherein said second modification is made such that said nucleic acid sequence is flanked upstream, downstream, or upstream and downstream by a nucleic acid sequence encoding a human immunoglobulin variable gene segment of said modified endogenous mouse immunoglobulin heavy chain locus, preferably wherein the first and second modifications are made simultaneously. 
provođenje druge modifikacije miša za dodavanje slijeda nukleinske kiseline koja prenosi aktivnost ADAM6 miša koja je funkcionalna u muškog miša, a navedeni slijed nukleinske kiseline kodira mišji protein ADAM6a ili ortolog, homolog ili njegov funkcionalni fragment i mišji protein ADAM6b ili njegov ortolog, homolog ili njegov funkcionalni fragment, pri čemu je navedena druga modifikacija izvedena tako da je navedeni niz nukleinskih kiselina flankiran uzvodno, nizvodno ili uzvodno i nizvodno slijedom nukleinskih kiselina koji kodira segment humanog imunoglobulina varijabilnog segmenta navedenog modificiranog endogenog mišjeg lokusa teškog lanca imunoglobulina, po mogućnosti pri čemu se prva i druga modifikacija izvode istovremeno.
The method of claim 1, wherein the mouse is male or wherein the mouse is female. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da je miš mužjak ili je miš ženka.
The method of claim 1 or 2, wherein said human immunoglobulin VH, DH, and JH gene segments comprise at least 18 human VH gene segments, 27 human DH gene segments, and six human JH gene segments that are operably linked to a mouse constant region gene after said first modification, or at least 39 human VH gene segments, 27 human DH gene segments, and six human JH gene segments that are operably linked to a mouse constant region gene after said first modification, or at least 80 human VH gene segments, 27 human DH gene segments, and six human JH gene segments that are operably linked to a mouse constant region gene after said first modification. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da navedeni humani imunoglobulin VH, DH i JH genski segmenti sadržavaju barem 18 humanih VH genskih segmenata, 27 humanih genskih segmenata DH i šest humanih JH genskih segmenata koji su operativno povezani s mišjim genom konstantne regije nakon navedene prve modifikacije, ili barem 39 humanih VH genskih segmenata, 27 humanih DH genskih segmenata i šest humanih JH genskih segmenata koji su operativno povezani s mišjim genom konstantne regije nakon navedene prve modifikacije, ili barem 80 humanih VH genskih segmenata, 27 humanih DH genskih segmenata i šest humanih JH genskih segmenata koji su operativno povezani s mišjim genom konstantne regije nakon navedene prve modifikacije.
The process of claim 2 or claim 3, wherein Lv is selected from hydrogen and a halogen, and R1 is selected from acetyl, trifluoroacetyl, phthalimidyl, benzyl, triphenylmethyl, benzylidenyl, p-toluenesulfonyl, p-methoxybenzyl, tertbutyloxycarbonyl, 9-fluorenylmethyloxycarbonyl and carbobenzyloxy. 
Postupak prema patentnom zahtjevu 2 ili zahtjevu 3, naznačen time, da je Lv odabrana od vodika i halogena, a R1 je odabrana od sljedećih: acetil, trifluoroacetil, ftalimidil, benzil, trifenilmetil, benzilidenil, p-toluensulfonil, p-metoksibenzil, tertbutiloksikarbonil, 9-fluorenilmetiloksikarbonil i karbobenziloksi.
brominating the compound or salt of Formula Vc to form the compound of Formula IV, or a salt thereof. 
brominacija spoja ili soli formule Vc u svrhu tvorbe spoja formule IV, ili njegove soli.
The process of any one of claims 1-11, wherein (a) R1 is an amino protecting group or (b) R1 is an amino protecting selected from acetyl, trifluoroacetyl, phthalimidyl, benzyl, triphenylmethyl, benzylidenyl, p-toluenesulfonyl, p-methoxybenzyl, tertbutyloxycarbonyl, 9-fluorenylmethyloxycarbonyl and carbobenzyloxy . 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 11, naznačen time, da (a) R1 je amino zaštitna skupina ili (b) R1 je amino zaštitna skupina koja je odabrana od acetila, trifluoroacetila, ftalimidila, benzila, trifenilmetila, benzilidenila, p-toluensulfonila, p-metoksibenzila, tertbutiloksikarbonila, 9-fluorenilmetiloksikarbonila i karbobenziloksi.
contacting a compound of Formula III, or a salt thereof, wherein R1 is hydrogen or an amino protecting group, with a metalating agent to form a compound of Formula I: or a salt thereof; 
dovođenje u doticaj spoja formule III: ili njegove soli, pri čemu R1 je vodik ili amino zaštitna skupina, s metalizacijskim sredstvom u svrhu tvorbe spoja formule I:
The compound of Formula Vb, Vc, IVb, IVc, or III: or a salt thereof; wherein R1 is hydrogen or an amino protecting group . 
Spoj, naznačen time, da je predstavljen sljedećim formulama Vb, Vc, IVb, IVc ili III: ili njegova sol, pri čemu R1 je vodik ili amino zaštitna skupina.
is substituted heterocycloalkoxy, substituted heterocycloalkylalkoxy, substituted heterocycloalkylamino or substituted heterocycloalkylalkylamino, wherein substituted heterocycloalkoxy, substituted heterocycloalkylalkoxy, substituted heterocycloalkylamino and substituted heterocycloalkylalkylamino are substituted with R11, R12 and R13; 
je supstituirani heterocikloalkoksi, supstituirani heterocikloalkilalkoksi, supstituirani heterocikloalkilamino ili supstituirani heterocikloalkilalkilamino, pri čemu su supstituirani heterocikloalkoksi, supstituirani heterocikloalkilalkoksi, supstituirani heterocikloalkilamino i supstituirani heterocikloalkilalkilamino supstituirani s R11, R12 i R13;
and R7 are independently selected from H or alkyl; 
i R7 su neovisno odabrani iz H i alkila;
A compound according to claim 1 or 2, wherein R3 is substituted heterocycloalkoxy, substituted heterocycloalkylalkoxy or substituted heterocycloalkylamino, wherein substituted heterocycloalkoxy, substituted heterocycloalkylalkoxy and substituted heterocycloalkylamino are substituted with R11, R12 and R13. 
Spoj u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da je R3 supstituirani heterocikloalkoksi, supstituirani heterocikloalkilalkoksi ili supstituirani heterocikloalkilamino, pri čemu su supstituirani heterocikloalkoksi, supstituirani heterocikloalkilalkoksi i supstituirani heterocikloalkilamino supstituirani s R11, R12 i R13.
is the ring system AJ; 
je sustav prstena AJ;
The crossing assembly according to any of claims 1-7, characterised in that gaps (18, 19) are formed in the base plate (5) running longitudinally in the interest of making the common crossing assembly lighter. 
Sklop raskrižja u skladu s bilo kojim od zahtjeva 1 do 7, naznačen time,da su oblikovani procjepi (18, 19) u temeljnoj pločici (5) koji prolaze uzdužno i služe u svrhu toga da se zajednički sklop raskrižja načini lakšim.
The crossing assembly according to claim 8, characterised in that the gaps (18, 19) preferably getting wider in the downwards direction essentially run along the entire length (b) of the base plate (5); their depth (m) changes in a way that follows the surface of the crossing assembly, and the volumes in the lightened cross-sections are preferably the same, their ratio preferably varies between a maximum of about 10-40%. 
Sklop raskrižja u skladu sa zahtjevom 8, naznačen time,da procjepi (18, 19) poželjno postaju širi u smjeru prema dolje i znatno prolaze uzduž cijele duljine (b) temeljne pločice (5); dok se njihova dubina (m) mijenja na takav način da, slijedi površinu sklopa raskrižja, i volumeni u ublaženim poprečnim presjecima su poželjno isti, dok se njihov omjer poželjno mijenja između jednog maksimuma od oko 10 do 40%.
The nucleic acid of claim 1, wherein the synthetic HIV envelope protein either: (a) further comprises a trimerization domain; or (b) comprises SEQ ID NO: 8 having a combination of mutations EK479-480RRRR, I529P, A471C and T575C. 
Nukleinska kiselina prema patentnom zahtjevu 1 ili 2, naznačena time što sintetski protein ovojnice HIV-a ili: (a) nadalje sadrži trimerizacijsku domenu, na primjer trimerizacijsku domenu koja ima aminokiselinsku sekvencu SEQ ID NO: 15 ili SEQ ID NO:16; ili (b) sadrži SEQ ID NO:8 koja ima kombinaciju mutacija EK479-480RRRR, I529P, A471C i T575C.
The vector of claim 8, comprising a left (5′) retroviral LTR, a Psi (Ψ) packaging signal, a central polypurine tract/DNA flap (cPPT/FLAP), a retroviral export element; a promoter operably linked to the polynucleotide encoding the CAR; and a right (3′) retroviral LTR. The vector of claim 9, further comprising a heterologous polyadenylation sequence. 
Vektor u skladu s bilo kojim od patentnih zahtjeva 2 do 4, naznačen time, što uključuje lijevi (5’) retrovirusni LTR, psi (Ψ) signal pakiranja, središnji polipurinski trakt/DNK prevjes (cPPT/FLAP), retrovirusni izvozni element; promotor operabilno povezan s polinukleotidom; i desni (3’) retrovirusni LTR.
point mutations), insertions, substitutions, deletions, frame shifts, single nucleotide polymorphisms (SNPs), haplotypes, chromosome abnormalities, copy number variation (CNV), epigenetics and DNA inversions. 
točkaste mutacije), insercije, supstitucije, delecije, pomake okvira, pojedinačne nukleotidne polimorfizme (SNP), haplotipove, kromosomske anomalije, varijaciju u broju kopija (CNV), epigenetike i DNK inverzije.
The method as defined in claim 2, wherein the genetic variations are selected from substitutions, insertions, deletions and frame shifts. 
Metoda definirana u zahtjevu 2, naznačena time što su genetske varijacije odabrane od supstitucija, insercija, delecija i pomaka okvira.
The method as defined in any one of claims 1 to 3, wherein the genetic variations are detected within the CACNA1A gene and the genetic variations are between 13,300,000 bp and 13,450,000 bp on chromosome 19. 
Metoda definirana u bilo kojem od zahtjeva 1 do 3, naznačena time što su genetske varijacije otkrivene unutar CACNA1A gena i što su genetske varijacije između 13,300,000 bp i 13,450,000 bp na kromosomu 19.
The method as defined in claim 8, wherein the genetic variations are selected from one or more of: 
Metoda definirana u zahtjevu 8, naznačena time što su genetske varijacije odabrane od jedne ili više:
a substitution and deletion mutation at 13,318,672 bp. 
mutacije supstitucije i delecije na 13,318,672 bp.
a frame shift mutation at 13,318,709 bp; 
mutacije pomaka okvira na 13,318,709 bp;
a substitution mutation at 140,918,181 bp. 
mutacije supstitucije na 140,918,181 bp.
a substitution mutation at 140,777,306 bp; and 
mutacije supstitucije na 140,777,306 bp; i
The method as defined in claim 5 or claim 6, wherein the genetic variations are selected from: 
Metoda definirana u zahtjevu 5 ili zahtjevu 6, naznačena time što su genetske varijacije odabrane od:
The method as defined in any one of claims 1 to 3, wherein the genetic variations are detected within the CACNA1B gene and the genetic variations are between 140,750,000 bp and 140,950,000 bp on chromosome 9. 
Metoda definirana u bilo kojem od zahtjeva 1 do 3, naznačena time što su genetske varijacije otkrivene unutar gena CACNA1B i što su genetske varijacije između 140,750,000 bp i 140,950,000 bp na kromosomu 9.
The method as defined in claim 9, wherein the genetic variations are selected from: (b) a substitution mutation at 140,772,440 bp. 
Metoda definirana u zahtjevu 9, naznačena time što su genetske varijacije odabrane od: mutacije supstitucije na 140,772,440 bp.
A pharmaceutical composition comprising a compound of claim 1, or a stereoisomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient. 
Farmaceutski sastav koji sadrži spoj prema bilo kojem od zahtjeva 1 do 3, ili njegovu farmaceutski prihvatljivu sol, i farmaceutski prihvatljivi nosač, razrjeđivač ili pomoćnu tvar.
A compound selected from the group consisting of: 
Spoj izabran iz grupe koji se sastoji od:
or a pharmaceutically acceptable salt thereof. 
(nastavak) Ili njegova farmaceutski prihvatljiva sol.
A pharmaceutical composition, comprising a compound of any one of claims 1-12 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, koji sadrži spoj prema bilo kojem od zahtjeva 1-12 ili njegovu farmaceutski prihvatljivu sol, i farmaceutski prihvatljiv nosač.
A composition for topical application, for use in obtaining the tissue repair of the nasal mucosa following nasal and sinus surgery, comprising an ester of alpha-tocopherol with a carboxylic acid of formula R-COOH, in which R is an alkyl radical having 1 to 19 carbon atoms, or an alkenyl or alkynyl radical having 2 to 19 carbon atoms, and an oily vehicle selected from the group consisting of hydrogenated polyisobutene, hydrogenated polydecene and mixtures of hydrogenated polyisobutene and/or hydrogenated polydecene with hydrogenated polyolefins, in particular hydrogenated C6-C14 polyolefins, Caprylic/Capric Triglyceride, Olus Oil, Adansonia Digitata Oil, Adansonia Digitata Seed Oil, Coco-Caprylate/Caprate, Olive Squalane, Olive Squalene, Sunflower (Helianthus Annus) Seed Oil, Simmondsia Chinensis Oil, Coco-Caprylate, Isononyl Isononanoate, Cyclopentasiloxane, and mixtures thereof. 
Pripravak za vanjsku primjenu, za uporabu u postizanju oporavka tkiva sluznice nosa poslije operacije nosa i sinusa, koja sadrži ester alfa-tokoferola s karboksilnom kiselinom formule R-COOH, u kojoj je R alkil radikal koji ima 1 do 19 atoma ugljika, ili alkenil ili alkinil radikal koji ima 2 do 19 atoma ugljika, i uljani nosač odabran iz grupe koja se sastoji od hidrogeniranog poliizobutena, hidrogeniranog polidecena i mješavina hidrogeniranog poliizobutena i/ili hidrogeniranog polidecena s hidrogeniranim poliolefinima, posebno hidrogeniranim C6-C14 poliolefinima, triglicerida kaprilne/kaprinske kiseline, biljnog ulja, ulja Adansonia digitata, ulja sjemena Adansonia digitata, kokosovog kaprilata/ kaprata, skvalana masline, skvalena masline, ulja sjemena suncokreta (Helianthus annus), ulja Simmondsia chinensis, kokosovog kaprilata, izononil izononanoata, ciklopentasiloksana, i njihovih smjesa.
A composition for topical application, for use in the treatment of chronic atrophic rhinitis, comprising an ester of alpha-tocopherol with a carboxylic acid of formula R-COOH, in which R is an alkyl radical having 1 to 19 carbon atoms, or an alkenyl or alkynyl radical having 2 to 19 carbon atoms, and an oily vehicle selected from the group consisting of hydrogenated polyisobutene, hydrogenated polydecene and mixtures of hydrogenated polyisobutene and/or hydrogenated polydecene with hydrogenated polyolefins, in particular hydrogenated C6-C14 polyolefins, Caprylic/Capric Triglyceride, Olus Oil, Adansonia Digitata Oil, Adansonia Digitata Seed Oil, Coco-Caprylate/Caprate, Olive Squalane, Olive Squalene, Sunflower (Helianthus Annus) Seed Oil, Simmondsia Chinensis Oil, Coco-Caprylate, Isononyl Isononanoate, Cyclopentasiloxane, and mixtures thereof. 
Pripravak za vanjsku primjenu, za uporabu u liječenju kroničnog atrofičnog rinitisa, koji sadrži ester alfa-tokoferola s karboksilnom kiselinom formule R-COOH, u kojoj je R alkil radikal koji ima 1 do 19 atoma ugljika, ili alkenil ili alkinil radikal koji ima 2 do 19 atoma ugljika, i uljani nosač odabran iz grupe koja se sastoji od hidrogeniranog poliizobutena, hidrogeniranog polidecena i mješavina hidrogeniranog poliizobutena i/ili hidrogeniranog polidecena s hidrogeniranim poliolefinima, posebno hidrogeniranim C6-C14 poliolefinima, triglicerida kaprilne/kaprinske kiseline, biljnog ulja, ulja Adansonia digitata, ulja sjemena Adansonia digitata, kokosovog kaprilata/kaprata, skvalana masline, skvalena masline, ulja sjemena suncokreta (Helianthus annus), ulja Simmondsia chinensis, kokosovog kaprilata, izononil izononanoata, ciklopentasiloksana, i njihovih smjesa.
The composition for the use according to any one of claims 1 and 2, wherein said ester of alpha-tocopherol is alpha-tocopheryl acetate, n-propionate or linoleate, preferably alpha-tocopheryl acetate. 
Pripravak za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 i 2, naznačen time što je navedeni ester alfa-tokoferola alfa-tokoferil acetat, n-propionat ili linoleat, poželjno alfa-tokoferil acetat.
The composition for the use according to claim 8, consisting of 10-30% alpha-tocopheryl acetate and 70-90% hydrogenated polydecene. 
Pripravak za uporabu u skladu s patentnim zahtjevom 8, koji se sastoji od 10-30% alfa-tokoferil acetata i 70-90% hidrogeniranog polidecena.
A wall dehumidification system, comprising: 
Sustav odvlaživanje zida, sadrži:
a generator (2) for a magnetic or electromagnetic field (E) to be directed toward a wall structure to be dehumidified; 
generator (2) za magnetsko ili elektromagnetsko polje (E) koje treba usmjeriti prema zidnoj konstrukciji koji treba odvlažiti;
means (5) for voltage powering said generator (2); 
sredstva (5) za napajanje naponom navedenog generatora (2);
System as claimed in claim 2, characterized in that said driving circuit (7) is of the ON/OFF type and is applied to said power stage (3) for generating said impulsive signal (S). 
Sustav sukladno patentnom zahtjevu 2, naznačen time što je navedeni pogonski krug (7) tipa UKLJUČENO/ISKLJUČENO i postavljeno je na navedeni stupanj (3) snage za generiranje navedenog impulsnog signala (S).
System as claimed in claim 3, characterized in that the frequency of said driving signal (S) is adjustable in a range between 10Hz and 10kHZ. 
Sustav sukladno patentnom zahtjevu 3, naznačen time što je frekvencija navedenog pogonskog signala (S) podesiva u opsegu između 10 Hz i 10 kHZ.
System as claimed in claim 1, characterized in that said timer (10) is programmable inside a time range between 1min and 10min. 
Sustav sukladno patentnom zahtjevu 1, naznačen time što je navedeni sat (10) programljivi unutar vremenskog opsega između 1 min i 10 min.
System as claimed in any preceding claim, characterized in that said power supply means (5) comprise a first adjustable power feeder (12) adapted to power said driving circuit (7) with a variable voltage to vary the power of said field (E). 
Sustav sukladno prethodnom patentnom zahtjevu, naznačen time što navedena sredstva (5) za električno napajanje sadrže prvi podesivi uređaj (12) za dovod električne energije prilagođen da napaja navedeno pogonski krug (7) s promjenljivim naponom da bi se varirala snaga navedenog polja (E).
System as claimed in claim 7, characterized in that said powering means (5) comprise a stabilized second power feeder (13) adapted to connect said central unit (6) to the electricity mains (R) to power the logic thereof with a predetermined and constant voltage. 
Sustav sukladno patentnom zahtjevu 7, naznačen time što navedeno sredstvo (5) za napajanje sadrži stabilizirani drugi uređaj (13) za dovod električne energije prilagođen da priključi navedenu središnju jedinicu (6) na napajanje električne mreže (R) da bi napajao njihovu logiku unaprijed određenim i konstantnim naponom.
The pharmaceutical composition for use of claim 3, wherein the disease, disorder, or medical condition is a mood disorder, a post-traumatic stress disorder, a panic disorder, an attention deficit disorder, cognitive deficiencies, or substance abuse. 
Farmaceutski sastav za upotrebu prema zahtjevu 3, gdje je bolest, poremećaj ili medicinsko stanje poremećaj raspoloženja, posttraumatski stresni poremećaj, panični poremećaj, poremećaj nedostatka pozornosti, kognitivni nedostaci, ili zloupotreba opojnih sredstava.
The pharmaceutical composition for use of claim 3, wherein the disease, disorder, or medical condition is a sleep disorder. 
Farmaceutski sastav za upotrebu prema zahtjevu 3, gdje je bolest, poremećaj ili medicinsko stanje poremećaj spavanja.
The pharmaceutical composition for use of claim 5, wherein the sleep disorder is a sleep-wake transition disorder, insomnia, restless legs syndrome, jet-lag, disturbed sleep, or a sleep disorder secondary to neurological disorders. 
Farmaceutski sastav za upotrebu prema zahtjevu 5, gdje je poremećaj spavanja poremećaj prelaska iz stanja sna u stanje budnosti, nesanica, sindrom nemirnih nogu, „jet-lag“, poremećeno spavanje, i sekundarni poremećaj spavanja u vezi s neurološkim poremećajima.
The pharmaceutical composition for use of claim 3, wherein the disease, disorder, or medical condition is a metabolic disorder. 
Farmaceutski sastav za upotrebu prema zahtjevu 3, gdje je bolest, poremećaj ili medicinsko stanje metabolički poremećaj .
The pharmaceutical composition for use of claim 7, wherein the metabolic disorder is overweight, obesity, insulin resistance, type II diabetes, hyperlipidemia, gallstones, angina, hypertension, breathlessness, tachycardia, infertility, sleep apnea, back and joint pain, varicose veins, or osteoarthritis. 
Farmaceutski sastav za upotrebu prema zahtjevu 7, gdje je metabolički poremećaj prekomjerna težina, pretilost, inzulinska rezistencija, dijabetes tipa II, hiperlipidemija, žučni kamenci, angina, hipertenzija, dispneja, tahikardija, neplodnost, apneja u snu, bol u leđima i zglobovima, proširene vene ili osteoartritis.
The pharmaceutical composition for use of claim 3, wherein the disease, disorder, or medical condition is a neurological disorder. 
Farmaceutski sastav za upotrebu prema zahtjevu 3, gdje je bolest, poremećaj ili medicinsko stanje, neurološki poremećaj.
The pharmaceutical composition for use of claim 9, wherein the neurological disorder is Parkinson's disease, Alzheimer's disease, Tourette's syndrome, catatonia, anxiety, delirium, or dementia. 
Farmaceutski sastav za upotrebu prema zahtjevu 9, gdje je neurološki poremećaj Parkinsonova bolest, Alzheimerova bolest, Touretteov sindrom, katatonija, anksioznost, delirij ili demencija.
The pharmaceutical composition of claim 11 in the form of a tablet, a capsule, a solution, an emulsion, or a suspension. 
Farmaceutski sastav prema zahtjevu 11 u obliku tablete, kapsule, otopine, emulzije ili suspenzije.
The pharmaceutical composition of claim 11 in the form of a tablet. 
Farmaceutski sastav prema zahtjevu 11 u obliku tablete.
The pharmaceutical composition of claim 14, wherein inert fillers are selected from sodium and calcium carbonate, sodium and calcium phosphate, lactose, starch, sugar, glucose, methyl cellulose, magnesium stearate, mannitol and sorbitol. 
Farmaceutski sastav prema zahtjevu 14, gdje su inertna sredstva za punjenje izabrana između natrijevog i kalcijevog karbonata, natrijevog i kalcijevog fosfata, laktoze, škroba, šećera, glukoze, metil celuloze, magnezijevog stearata, manitola i sorbitola .
The pharmaceutical composition of claim 14, wherein disintegrating agents are selected from starch, polyvinyl-pyrrolidone (PVP), sodium starch glycolate, microcrystalline cellulose, and alginic acid. 
Farmaceutski sastav prema zahtjevu 14, gdje su sredstva za raspadanje izabrana između škroba, polivinilpirolidona (PVP), natrijev škrob glikolata, mikrokristalične celuloze i alginske kiseline.
The pharmaceutical composition of claim 14, wherein binding agents are selected from starch and gelatin. 
Farmaceutski sastav prema zahtjevu 14, gdje su vezivna sredstva izabrana između škroba i želatine.
The pharmaceutical composition of claim 14 wherein lubricating agents are selected from magnesium stearate, stearic acid and talc. 
Farmaceutski sastav prema zahtjevu 14, gdje su maziva sredstva izabrana između magnezijevog stearata, stearinske kiseline i talka.
The pharmaceutical composition of claim 11 in the form of a capsule. 
Farmaceutski sastav prema zahtjevu 11 u obliku kapsule.
The anti-FcRn antibody or binding fragment thereof according to claim 1, wherein the antibody or binding fragment is conjugated to a polymer and said polymer is starch, albumin, or polyethylene glycol. 
Anti-FcRn antitijelo ili njegov vezujući fragment prema bilo kojem patentnom zahtjevu od 1 do 4, naznačen time, što je antitijelo ili vezujući fragment konjugiran na polimer, primjerice odabran iz škroba, albumina i polietilenglikola.